

## INHIBITION OF THE OXIDANT-INDUCED REDUCTION OF CYTOCHROME *b* BY A SYNTHETIC ANALOGUE OF UBIQUINONE

John R. BOWYER and Bernard L. TRUMPOWER

*Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755, USA*

Received 16 April 1980

### 1. Introduction

The mechanism of electron transfer through the cytochrome (cyt.) *b*-*c*<sub>1</sub> segment of the mitochondrial respiratory chain is not understood. An especially enigmatic aspect of this electron transfer process is the phenomenon known as the 'oxidant-induced reduction of cyt. *b*' whereby addition of an oxidant to mitochondria in which cyt. *c*<sub>1</sub> is reduced and the *b* cytochromes are oxidized results in transient reduction of cyt. *b* coincident with cyt. *c*<sub>1</sub> oxidation [1-3]. The oxidant-induced reduction of cyt. *b* requires a source of reducing equivalents (succinate, NADH, or ubiquinol), depends on the presence of ubiquinone [1], and involves both cyt. *b*-562 and *b*-566 [2]. Although the reduction of cyt. *b* is most readily demonstrated in the presence of antimycin, a comparable oxidant-induced reduction can be observed at low temperatures [4], which indicates this reaction is intrinsic to the mechanism of electron transfer in the cyt. *b*-*c*<sub>1</sub> segment and not an aberrant response elicited by this inhibitor.

The oxidant-induced reduction of cyt. *b* is not readily explained by a classical linear mechanism of electron transfer through the cyt. *b*-*c*<sub>1</sub> segment. Wikström and Berden [2] suggested that reduction of the *b* cytochromes is obligatorily linked to reduction of cyt. *c*<sub>1</sub> via a common ubisemiquinone intermediate. Mitchell incorporated features of the Wikström-Berden mechanism into the protonmotive Q cycle [5] and thus provided the simplest explanation to date for the oxidant-induced reduction of cyt. *b*. According to the Q cycle hypothesis, ubiquinol is oxidized at the cytoplasmic side of the inner mitochondrial membrane by transfer of an electron to cyt. *c*<sub>1</sub>, and the low potential ubisemiquinone which is formed then reduces cyt. *b*. Thus, a central

premise of the Q cycle hypothesis is that high potential oxidants, such as ferricyanide, generate the prerequisite ubisemiquinone reductant for cyt. *b* by oxidizing ubiquinol via cyt. *c*<sub>1</sub> and the iron-sulfur protein of the cyt. *b*-*c*<sub>1</sub> segment [6,7].

The proposed protonmotive Q cycle therefore assigns a uniquely important role to the oxidation-reduction reactions of ubiquinone in the oxidant-induced reduction of cyt. *b*. This paper reports that a synthetic analogue of ubiquinone, 5-*n*-undecyl-6-hydroxy-4,7-dioxobenzothiazole (UHDBT), inhibits the oxidant-induced reduction of cyt. *b* in isolated succinate-cyt. *c* reductase complex.

### 2. Methods

Succinate-cyt. *c* reductase complex was isolated from bovine heart mitochondria [8]. To demonstrate oxidant-induced reduction of cyt. *b*, reductase complex was suspended at 0.36  $\mu$ M, based on cyt. *c*<sub>1</sub> content, in 0.1 M sodium phosphate, 0.5 mM EDTA, 0.5% cholate, 0.25 mM KCN (pH 7.2) and placed in an open, stirred cuvette at 27°C. Cytochrome *c*<sub>1</sub> was first reduced by addition of 30-70  $\mu$ M ascorbate. Antimycin and succinate were then added as indicated in the figure legends. Under these conditions the cyt. *b* remains fully oxidized, due to the inability of succinate to reduce cyt. *b* in the presence of antimycin when cyt. *c*<sub>1</sub> is reduced by ascorbate [9], and this was checked spectrally at the beginning of each experiment.

Reduction of cyt. *b* was then initiated by addition of ferricyanide as indicated in the figure legends. Kinetics of cyt. *b* reduction were monitored with an Aminco DW 2a dual-wavelength spectrophotometer using the wavelength pairs 563 versus 575 nm and a

2 nm bandpass to include contributions from cyt. *b*-562 and *b*-566. Oxidation–reduction of cyt. *c*<sub>1</sub> was monitored at 553 versus 539 nm. To establish the oxidation–reduction status of the cytochromes before and after each kinetics experiment, spectra were scanned from 535–585 nm in the dual-beam mode. Absorption difference spectra as shown in fig.2 were obtained on a Cary 118 recording spectrophotometer. UHDBT was synthesized as in [10] with minor modifications [11].

### 3. Results

When succinate is added to isolated succinate–cyt. *c* reductase complex in the absence of inhibitors, ~75% of the dithionite-reducible cyt. *b* is reduced [8,9,12]. This cyt. *b* consists of cyt. *b*-562 and a portion of the low potential cyt. *b*-566 [13], while the residual dithionite-reducible cyt. *b* consists mainly of cyt. *b*-566 [13]. If antimycin is added to isolated reductase complex and cyt. *c*<sub>1</sub> and the iron–sulfur protein of the cyt. *b*–*c*<sub>1</sub> segment [14] are reduced by addition of ascorbate, there is no significant reduction of cyt. *b* for several minutes after succinate addition, reflecting a 14 000-fold increase in the half-time for cyt. *b* reduction under these conditions [13]. However, if ferricyanide is added during this time interval when there is otherwise no appreciable reduction of cyt. *b*, the oxidant induces a rapid reduction of cyt. *b* [9].

The tracing in fig.1a shows this oxidant-induced reduction of cyt. *b* in isolated reductase complex. The amount of cyt. *b* reduced is ~60% of the dithionite reducible cyt. *b* monitored at 563–575 nm. Addition of 1  $\mu$ M UHDBT almost completely abolishes the oxidant-induced reduction as shown in fig.1b. As shown in [15], a similar oxidant-induced reduction of cyt. *b*, although smaller in magnitude, can be demonstrated with ubiquinol-2 as a source of reducing equivalents instead of succinate. This oxidant-induced reduction is also inhibited by UHDBT (not shown).

The kinetics of the oxidant-induced cyt. *b* reduction (fig.1a) are very similar to the kinetics of cyt. *c*<sub>1</sub> oxidation which results from addition of ferricyanide (fig.1c). Increasing the concentration of ferricyanide accelerates the initial rates of both cyt. *c*<sub>1</sub> oxidation and cyt. *b* reduction, although the final extent of the latter is diminished (results not shown),




Fig.1. Inhibition of the oxidant-induced reduction of cyt. *b* in isolated succinate–cyt. *c* reductase complex by 5- $\pi$ -undecyl-6-hydroxy-4,7-dioxobenzothiazole. Reductase complex was suspended as in section 2. For the reaction shown by tracing (a) ascorbate was added to reduce cyt. *c*<sub>1</sub>, followed by 3  $\mu$ M antimycin and 5 mM succinate. Reduction of cyt. *b* was then induced by addition of 4  $\mu$ M ferricyanide 2 min after addition of the succinate. The reaction shown in tracing (b) was performed under the same conditions, except that 1  $\mu$ M UHDBT was added prior to addition of ferricyanide. Tracing (c) shows the oxidation of cyt. *c*<sub>1</sub> during the oxidant-induced reduction of cyt. *b* in the absence of UHDBT. The reaction was carried out under conditions identical to those of fig.1a.

presumably owing to a direct reaction between ferricyanide and ferrocytochrome *b* and/or its physiological reductant. UHDBT does not inhibit the initial phase of cyt. *c*<sub>1</sub> oxidation by ferricyanide, but the subsequent rereduction is inhibited (not shown).

A spectrum of the cyt. *b* which is reduced by oxidant-induced reduction is shown in fig.2a. The  $A_{564}$  max indicates that this cyt. *b* population consists primarily of cyt. *b*-562, the absorption maximum of which is shifted slightly to the red by antimycin [16], and probably a small contribution from cyt. *b*-566.




Fig.2. Absorption difference spectra of the *b* cytochromes reduced by oxidant-induced reduction. The spectrum in (a) is of cyt. *b* reduced by addition of ferricyanide to a sample in which cyt. *c*<sub>1</sub> was reduced and the *b* cytochromes were completely oxidized prior to addition of oxidant. Reductase complex was suspended at 1.62  $\mu$ M in the reference and sample cuvettes of a split beam spectrophotometer, and cyt. *c*<sub>1</sub> was reduced in both cuvettes by addition of ascorbate. To the sample cuvette, 11.2  $\mu$ M antimycin was added followed by 15 mM succinate. A spectrum was then recorded to insure that the cyt. *b* was initially oxidized. Reduction of cyt. *b* was then induced by addition of 15  $\mu$ M ferricyanide. The spectrum of reduced cyt. *b* was scanned after  $\sim$ 2 min to allow re-reduction of cyt. *c*<sub>1</sub> (see fig.1). The spectrum in (b) shows the oxidant-induced reduction of the low potential cyt. *b*-566 which results when oxidant is added after reduction of cyt. *b*-562 by succinate. The protocol was similar to that in (a), except that succinate was added prior to antimycin. A spectrum was then recorded to confirm that succinate had reduced  $\sim$ 70% of the total cyt. *b*. The reference cuvette was similarly treated, and a spectrum recorded to show that the redox states of the cytochromes in the two cuvettes were identical, after which 7.5  $\mu$ M ferricyanide was added to the sample. After an interval to allow re-reduction of cyt. *c*<sub>1</sub>, the difference spectrum of succinate-reduced plus oxidant-reduced cyt. *b* versus succinate-reduced cyt. *b* was recorded.

When succinate is added to isolated reductase complex in the presence or absence of antimycin, but without prior reduction of cyt. *c*<sub>1</sub> by ascorbate, the cyt. *b* which is reduced consists mostly of cyt. *b*-562 [8,9,12]. The low potential cyt. *b*-566 which remains oxidized can subsequently be reduced by an oxidant-induced reduction. The spectrum of this low potential reduced cyt. *b*, shown in fig.2b, has a maximum at 566 nm and a shoulder at 558 nm, characteristic of cyt. *b*-566. The tracing in fig.3a shows the selective oxidant-induced reduction of the low potential cyt. *b*. Addition of UHDBT in the pres-




Fig.3. Inhibition of oxidant-induced reduction of low potential cyt. *b*-566 by UHDBT. Succinate was added to reductase complex to reduce cyt. *c*<sub>1</sub> and  $\sim$ 70% of the cyt. *b*. After reduction of cyt. *b* attained an almost constant level, as monitored at 566–575 nm, 3  $\mu$ M antimycin was added. Oxidant-induced reduction of the cyt. *b* not pre-reduced by succinate was then initiated by addition of 2  $\mu$ M ferricyanide. Where indicated, 1  $\mu$ M UHDBT was added.

ence of antimycin results in a slow reoxidation of a fraction of the reduced cyt. *b* (not shown). However, this oxidation rate is considerably slower than the rate of the ferricyanide-induced reduction of cyt. *b*-566, and UHDBT clearly inhibits the latter process (fig.3b). These results show that UHDBT inhibits oxidant-induced reduction of both cyt. *b*-562 and *b*-566.

#### 4. Discussion

There is now extensive evidence, from experiments with yeast mitochondria [17] and bovine heart mitochondrial succinate–cyt. *c* reductase complex [11], that UHDBT is a highly potent and specific inhibitor

of electron transfer in the cyt. *b*-*c*<sub>1</sub> segment of the respiratory chain. This compound also inhibits rereduction of photo-oxidized cyt. *c*<sub>2</sub> and photo-reduction of cyt. *b* in purple non-sulfur photosynthetic bacteria [18,19], and recent results indicate that the inhibitor blocks electron transfer between the Rieske-type iron-sulfur cluster and cyt. *c*<sub>2</sub> in these organisms, possibly by binding to the iron-sulfur protein (J. R. B., P. L. Dutton, R. C. Prince, A. R. Crofts, submitted).

The results presented here show for the first time that UHDBT inhibits the oxidant-induced reduction of cyt. *b*. Because UHDBT is structurally similar to ubiquinone, it seems likely that this inhibitor interferes with normal ubiquinone function. If this rationale is correct, our findings provide evidence that oxidation-reduction of ubiquinone is involved in the oxidant-induced reduction of cyt. *b*.

Inhibition of the oxidant-induced reduction of cyt. *b* by UHDBT is also of interest because of the hypothesis that the iron-sulfur protein of the cyt. *b*-*c*<sub>1</sub> segment functions as a ubiquinol/cyt. *c*<sub>1</sub>-ubisemiquinone/cyt. *b* oxidoreductase in a protonmotive Q cycle mechanism [6,7]. According to this proposal, the iron-sulfur protein would participate in the oxidant-induced reduction of cyt. *b* by transferring an electron from ubiquinol to cyt. *c*<sub>1</sub>, thus generating the ubisemiquinone reductant for cyt. *b*. The finding that UHDBT appears to interact with the Rieske-type iron-sulfur protein in photosynthetic bacteria (see above) is noteworthy in this regard. The availability of reconstitutively active iron-sulfur protein from mammalian mitochondria [20] will permit experimentation to test whether UHDBT and ubiquinol interact with the isolated iron-sulfur protein.

### Acknowledgements

This work was supported by an NIH research grant GM 20379. B. L. T. is an Established Investigator of the American Heart Association.

### References

- [1] Erecinska, M., Chance, B., Wilson, D. F. and Dutton, P. L. (1972) *Proc. Natl. Acad. Sci. USA* 69, 50-54.
- [2] Wikström, M. K. F. and Berden, J. (1972) *Biochim. Biophys. Acta* 283, 403-420.
- [3] Chance, B. (1974) in: *Dynamics of energy-transducing membranes* (Ernster, L. et al. eds) pp. 553-578, Elsevier/North-Holland, Amsterdam, New York.
- [4] Erecinska, M. and Wilson, D. F. (1972) *FEBS Lett.* 24, 269-272.
- [5] Mitchell, P. (1976) *J. Theor. Biol.* 62, 327-367.
- [6] Trumpower, B. L. (1976) *Biochem. Biophys. Res. Commun.* 70, 73-80.
- [7] Trumpower, B. L. and Edwards, C. A. (1979) *FEBS Lett.* 100, 13-16.
- [8] Trumpower, B. L. and Simmons, Z. (1979) *J. Biol. Chem.* 254, 4608-4616.
- [9] Trumpower, B. L. and Katki, A. (1975) *Biochem. Biophys. Res. Commun.* 65, 16-23.
- [10] Friedman, M. D., Stotter, P. L., Porter, T. H. and Folkers, K. (1973) *J. Med. Chem.* 16, 1314-1316.
- [11] Trumpower, B. L. and Haggerty, J. G. (1980) *J. Bioenerg. Biomembr.* in press.
- [12] Erecinska, M. and Wilson, D. F. (1972) *FEBS Lett.* 24, 269-272.
- [13] Trumpower, B. L. and Katki, A. (1979) in: *Membrane proteins in energy transduction* (Capaldi, R. A. ed) pp. 89-200, Marcel Dekker, New York.
- [14] Rieske, J. S., MacLennan, D. H. and Coleman, R. (1964) *Biochem. Biophys. Res. Commun.* 15, 338-344.
- [15] Rieske, J. S. (1971) *Arch. Biochem. Biophys.* 145, 179-193.
- [16] Berden, J. A. and Opperdoes, F. R. (1972) *Biochim. Biophys. Acta* 267, 7-14.
- [17] Roberts, H., Choo, W. M., Smith, S. C., Marzuki, S., Linnane, A. W., Porter, T. H. and Folkers, K. (1978) *Arch. Biochem. Biophys.* 191, 306-315.
- [18] Bowyer, J. R. and Crofts, A. R. (1978) in: *Frontiers of biological energetics* (Dutton, P. L. et al. eds) vol. 1, pp. 326-333, Academic Press, New York.
- [19] Bowyer, J. R., Tierney, G. V. and Crofts, A. R. (1979) *FEBS Lett.* 101, 207-212.
- [20] Trumpower, B. L. and Edwards, C. A. (1979) *J. Biol. Chem.* 254, 8697-8706.